[A change in the prescription of thrombolytic treatment in elderly patients. The experience of the Hospital de León].
OBJECTIVE
Most deaths caused from AMI occur in elderly patients, and it is know that these patients way also benefit from the type treatment normally offered to younger patients. We proposed to analyse how our therapeutic strategy has evolved for patients of advanced age related to the admission in the CCU and the prescription of thrombolytic treatment.


METHODS
In order to carry our investigation, we compared the clinical profile, the treatment and the results of patients over the age of 70 who were hospitalized in our Service with suspected AMI during last 3 years. A total number of 366 which were divided into two consecutive periods of 18 months; 176 patients from January'91 to June'92 (Period I--former--) and 190 patients from July'92 to December'93 (Period II--latter--).


RESULTS
In both periods, nearly all patients with suspected AMI and < 48 hours of since symptoms began were hospitalized in the CCU irrespective of their age. In both periods, over 40% of the total number of patients admitted to CCU were > 70 years (I: 45.2% vs II: 42.6%). We observed that in the latter group a major part of patients had complicated AMI at the moment of admittance (I: 15.3% vs II: 24.2%; p < 0.05). This is probably related to a less favorable clinical profile. Despite this, a parallel increase in hospital death rate was not observed (I: 21% vs II: 17%; p: NS). Over time, the ratio of patients prescribed with thrombolysis > 70 was nearly doubled (I: 13.7% vs II: 24.7%; p < 0.01), without a detected increase in complications of hemorrhages.


CONCLUSIONS
For a variety of factors, the number of elderly patients admitted with complicated AMI has increased. In our experience the simple modification in the way thrombolysis is prescribed is capable of restraining the hospital death rate ratio.
Alonso-Orcajo
N
N
Servicio de Cardiología, Hospital del INSALUD, León.
Franco Aranda
C
C
García Calabozo
R
R
Fidalgo Andrés
M L
ML
Rodríguez García
M A
MA
Bayón Fernández
J
J
García Porrero
E
E
Martínez-Sande
J L
JL
Simarro
E
E
D000368:Aged; D016255:Anistreplase / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D005260:Female; D017052:Hospital Mortality; D006769:Hospitals, General / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D011994:Recombinant Proteins / Q000008:administration & dosage; D013030:Spain / Q000453:epidemiology; D013300:Streptokinase / Q000008:administration & dosage*; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*
D011994:Recombinant Proteins; D016255:Anistreplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator
Cambio en la prescipción de tratamiento trombolítico en pacientes ancianos. Experiencia del Hospital de León.